Agios Pharmaceuticals is a biopharmaceutical company passionately committed to applying its scientific leadership in the field of cellular metabolism to transform the lives of patients with cancer and rare genetic disorders of metabolism, which are a subset of orphan genetic metabolic diseases.

Agios is a first mover in using cellular metabolism, an unexploited area of biological research with disruptive potential, as a platform for developing potentially transformative medicines. The Company intends to apply its deep understanding of metabolism, coupled with its ability to create medicines that can inhibit or activate metabolic enzymes, to fundamentally change the way cancer and rare genetic disorders of metabolism are treated.

Agios also develops drugs that focus on glycolysis, fatty acid metabolism, and autophagy. The Company's therapeutics are used in the areas of autoimmune, inflammatory, and neurological diseases.

Type
Public
HQ
Cambridge, US
Founded
2008
Size (employees)
382 (est)+34%
Website
agios.com
Agios Pharmaceuticals was founded in 2008 and is headquartered in Cambridge, US
Report incorrect company information

Key People/Management at Agios Pharmaceuticals

David Schenkein

David Schenkein

CEO
Scott Biller

Scott Biller

Chief Scientific Officer
Chris Bowden

Chris Bowden

Chief Medical Officer
Andrew Hirsch

Andrew Hirsch

Chief Financial Officer and Head of Corporate Development
Steve Hoerter

Steve Hoerter

Chief Commercial Officer
Melissa McLaughlin

Melissa McLaughlin

Chief People Officer
Show more

Agios Pharmaceuticals Office Locations

Agios Pharmaceuticals has an office in Cambridge
Cambridge, US (HQ)
88 Sidney St
Show all (1)
Report incorrect company information

Agios Pharmaceuticals Financials and Metrics

Agios Pharmaceuticals Financials

Agios Pharmaceuticals's revenue was reported to be $43.01 m in FY, 2017
USD

Revenue (Q1, 2018)

8.8 m

Net income (Q1, 2018)

(90.8 m)

EBIT (Q1, 2018)

(94 m)

Market capitalization (14-Jun-2018)

5.4 b

Closing share price (14-Jun-2018)

93.7

Cash (31-Mar-2018)

364.5 m
Agios Pharmaceuticals's current market capitalization is $5.4 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

25.5 m65.4 m59.1 m69.9 m43 m

Revenue growth, %

156%(10%)18%

General and administrative expense

71.1 m

R&D expense

292.7 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Revenue

6.3 m8.4 m34.2 m13.2 m5.5 m31.3 m7 m9 m10.5 m11.4 m8.8 m

General and administrative expense

2.5 m3.3 m4.2 m5.2 m7 m8.9 m9.9 m10.8 m12.6 m11.9 m14.8 m16.1 m17.5 m24.6 m

R&D expense

14.8 m17.4 m22.6 m25.5 m32.4 m36.4 m36 m44 m50.8 m60.6 m62.7 m79.8 m72.9 m78.2 m

Operating expense total

17.3 m20.7 m26.7 m30.7 m39.4 m45.4 m46 m54.9 m63.4 m72.5 m77.6 m95.9 m90.4 m102.8 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

71.6 m14 m71.8 m160.8 m102.7 m

Accounts Receivable

2.3 m600 k

Inventories

2.5 m4.8 m8.7 m10.3 m

Current Assets

169.7 m359.5 m337.3 m559.9 m445.3 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Cash

106 m32.8 m108.2 m70 m35.3 m72.5 m80 m39 m234 m285.5 m200.3 m138.7 m132.7 m364.5 m

Current Assets

198.8 m172.4 m245.2 m247.6 m364.1 m390.2 m371.7 m329.5 m484.2 m600.9 m506.9 m604.7 m528.3 m803 m

PP&E

3.6 m3.5 m3.2 m3.7 m14.3 m19.3 m21.1 m23 m25.1 m26.3 m24.1 m24.8 m24 m23.7 m

Total Assets

219.1 m181.9 m272 m269.6 m474.3 m474.4 m449.1 m396.1 m557.6 m672 m557.3 m760.6 m687.2 m1 b
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(39.4 m)(53.5 m)(117.7 m)(198.5 m)(314.7 m)

Depreciation and Amortization

1.4 m1.4 m3.3 m5.7 m6.4 m

Inventories

Accounts Payable

30 k7.6 m4.2 m3.5 m5.3 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Net Income

(11.2 m)(12.2 m)(18.3 m)3.7 m(5 m)(36.9 m)(77.1 m)(23.2 m)(79.2 m)(142 m)(66.2 m)(149.2 m)(226.4 m)(90.8 m)

Depreciation and Amortization

1.2 m2.2 m1.2 m2.6 m4 m1.6 m3.2 m4.8 m1.7 m

Accounts Payable

5.4 m6.2 m12.6 m(1.2 m)(1.3 m)(293 k)3.8 m1.7 m(994 k)4.9 m742 k(4.5 m)

Cash From Operating Activities

(21.6 m)(46.4 m)(19 m)138.8 m89.8 m(74.1 m)(133.1 m)(210.8 m)(99 m)
USDY, 2018

Financial Leverage

1.2 x
Show all financial metrics
Report incorrect company information

Agios Pharmaceuticals Online and Social Media Presence

Embed Graph
Report incorrect company information